Developing a new antiviral treatment for COVID-19
Official title: IND-Enabling Development of a Small Molecule COVID Therapeutic
Funded at Oyagen, INC. · NIH-10813199 · Data updated 2026-11-12
This study is testing a new antiviral drug called sangivamycin to see how well it works against COVID-19 in hamsters, with hopes that it could eventually help people fighting the virus.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oyagen, INC. NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $300,000 |
| NIH project number | 5R43AI167113-02 |
| Project ID | NIH-10813199 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals who are at risk of severe COVID-19 infection or those who have tested positive for the virus.
✕Less likely to help
Patients who are not infected with COVID-19 or those who have already recovered from the virus may not benefit from this research.
What this research studies
This research focuses on the development of sangivamycin, an antiviral compound, to treat COVID-19. The project will assess how the drug works in the body and its effectiveness against the virus in animal models, specifically Golden Syrian hamsters. The goal is to gather the necessary data to support an application for clinical trials in humans, which could lead to new treatment options for COVID-19 patients. The research builds on previous findings that showed sangivamycin's potential against various COVID-19 variants.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from COVID-19.
How similar studies have gone: Previous research has shown promise with similar antiviral compounds, but this specific approach with sangivamycin is novel and untested in the context of COVID-19.
Where this research is happening
-
Oyagen, INC.
Rochester, United States Active
Researchers
- Principal investigator: Bennett, Ryan P — Oyagen, INC.
- Study coordinator: Bennett, Ryan P
Related research
Other NIH-funded projects on the same topics.
-
Finding new drugs to fight Ebola by targeting a specific viral protein.
This study is looking for new medicines to help fight Ebola by testing a huge number of small compounds to see which ones can stop a key part of the virus from working, aiming to find quick treatments that can help patients during outbreaks.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.